Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
274
resultados
Última actualización
28/08/2026 [06:57:00]
Resultados 225 a 250 de 274
Resumen de: WO2026169809A1
Provided herein are methods of preventing and/or treating vesicant agent induced ocular injury. The methods comprise treating the eyes of a subject injured or at risk of being injured by a vesicant agent with dexamethasone sodium phosphate (DSP) loaded nanoparticles. In some aspects, the vesicant agent is mustard gas.
Resumen de: US20260234115A1
0000 The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).
Resumen de: US20260232849A1
0000 Compositions, methods, and kits relating to substantially monodisperse, ultrasound targeted nanobubble compositions are disclosed. The nanobubble compositions comprise a hollow core containing at least one gas and a polymer shell encircling the hollow core. Methods of producing the substantially monodisperse nanobubble compositions using an ultrasound shearing-based fabrication method are disclosed. Methods of using the nanobubble compositions are also disclosed.
Resumen de: US20260232601A1
Disclosed herein are functionalized polyethylenimine compounds for use as nanoparticles. Methods of making the compounds and nanoparticles comprising a cargo and methods of delivering a nanoparticle comprising a cargo are provided. The nanoparticles of the present invention can be utilized in methods of delivering cargo in a tissue specific manner, providing low toxicity and efficient release of cargo in the cell.
Resumen de: US20260234204A1
The invention relates to truncated isolated BRK peptides and functional peptides thereof that inhibit the phosphorylation of p27Kip1 and the resulting kinase activity of CDK2 and CDK4; and to pharmaceutical compositions thereof. The invention further relates to the use of the isolated peptides in methods of treating cancer in subject in need thereof. The methods of treating cancer include methods of treating pancreatic cancer.
Resumen de: US20260232813A1
0000 A therapeutic nanoligomer composition includes at least a peptide nucleic acid (PNA), the at least a PNA including a sequence of nucleobases capable of interacting with a gene target in a target host and a polypeptide backbone attached to the sequence of nucleobases, the polypeptide backbone including a plurality of amino acid units, wherein the plurality of amino acid units includes at least a 2-N-aminoethylglycine unit; and a transport domain, the transport domain including a delivery nanoparticle and a cellular uptake domain (CUD) associated with the delivery nanoparticle, wherein the delivery nanoparticle is attached to the at least a PNA, and wherein the CUD includes a hydrophilic polymeric coating or one or more weakly charged surface groups.
Resumen de: US20260232836A1
The present disclosure relates, in part, to polypeptide-conjugated lipid nanoparticle (LNP) compositions, and methods of use thereof for brain-targeted delivery of therapeutic cargo. In another aspect, the disclosure provides methods for treating, preventing, and/or ameliorating disease and/or disorders of the brain (e.g., neurological disease and/or disorders).
Resumen de: US20260232838A1
Provided herein are synthetic melanin nanoparticles and methods useful for protecting cell-free reactions from prolonged solar and UV exposure.
Resumen de: WO2026169269A2
Provided herein are compositions comprising peptide-based nanoparticles. In some embodiments, the peptide-based nanoparticles each comprise a perfluorocarbon liquid core and a plurality of amphiphilic peptides surrounding the perfluorocarbon liquid core. In some embodiments, the amphiphilic peptides comprise a peptide analogue of Apolipoprotein A1. Also provided herein are methods of preparing any of the compositions described herein, as well as methods of treating atherosclerotic plaque formation using any of the composition described herein.
Resumen de: WO2026169723A1
The present disclosure provides, among other things, improved lipid nanoparticles and improved methods of making lipid nanoparticles.
Resumen de: US20260232806A1
0000 Aspects describe nanoparticle-delivered adenyl cyclase activators (e.g., forskolin via LCMSN) to induce sWAT browning, enhancing thermogenesis for wound healing and cold injury protection. Applications include chronic wounds, diabetic ulcers, burns, frostbite, and hypothermia via subcutaneous or transdermal routes, with demonstrated acceleration of closure, reduced inflammation/necrosis, and improved angiogenesis/ECM remodeling in frostbite models.
Resumen de: WO2026166986A1
The present disclosure provides a compound of formula I: I or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions and suspensions comprising the compound of formula I, as well as uses thereof.
Resumen de: US20260232777A1
The present invention relates to a pharmaceutical combination comprising (i) at least one nucleic acid comprising an antisense and flipped sequence of a fragment of a sequence coding for a kanamycin resistance protein and (ii) at least one non-immunosuppressive inducer of tumor cell apoptosis, wherein said nucleic acid is formulated with a nano-vehicle. Said nucleic acid is preferably pVAX14 plasmid, said non-immunosuppressive inducer of tumor cell apoptosis is preferably ATRA, an arsenic-related compound or azacytidine. The present invention also relates to the pharmaceutical combination as defined above for use in the treatment of cancer or infectious diseases, by activating the innate immune pathway and immunological cell death pathway. Pathway analyses of gene expression profiles revealed a DNA activated gene list regulated in 16 immune pathways. This gene list provides biomarkers of response to DNA treatment.
Resumen de: US20260232839A1
The present disclosure is a lipid nanoparticle including a composition including a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, in which the polymer and the protein have opposite charges at a predetermined pH. The lipid nanoparticle preferably has a protein encapsulated therein. In addition, when the particle diameter of the lipid nanoparticles is measured, the peak top of the particle diameter distribution is preferably at 80 nm to 120 nm.
Resumen de: WO2026169218A1
The present invention is a development of a vaccine formulation or a vaccine composition for inducing antigen-specific cells to generate immunity for resistance against Mycobacterium tuberculosis, comprising Bacillus Calmette-Guérin (BCG), ESAT-6 protein (ESAT-6) encapsulated with a nanoparticle-type carrier, and a STING ligand, wherein the BCG, the ESAT- 6 protein encapsulated with the nanoparticle-type carrier, and the STING ligand are physically and/or chemically combined, with a mass ratio of ESAT-6 to the STING ligand being in a range of 4-10 : 1, and wherein the vaccine composition according to the present invention is administered by a prime-pool strategy for preventing pulmonary tuberculosis infection.
Resumen de: WO2026168562A1
Problem To provide a bubble preparation capable of significantly suppressing a tumor and efficiently delivering a drug or the like to a site such as a tumor when used together with low-intensity therapeutic ultrasound. Solution A bubble preparation which exhibits a tumor suppressing effect when low-intensity therapeutic ultrasound is applied to the bubble preparation, the bubble preparation being characterized by comprising a coating film, which comprises a lipid, and a gas enclosed in the lumen of the coating film, wherein the coating film is an anionic lipid containing at least distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG), and the gas contains at least one of perfluoropropane, perfluorobutane, perfluoropentane, and perfluorohexane, or a mixed gas.
Resumen de: WO2026169759A1
The present disclosure relates generally to compositions and methods for in vivo gene therapy, and more specifically to delivering mRNA encoding anti-CD19 chimeric antigen receptors (CARs) to immune cells (e.g., T cells, such as CD8+ T cells) in vivo.
Resumen de: US20260232758A1
An exemplary embodiment of the present disclosure provides an intracellular delivery complex, comprising at least one biomacromolecule, each of the at least one biomacromolecules having a first ionic net charge, and at least one hydrophobic counterion, each of the at least one hydrophobic counterions having a second ionic net charge opposite the first ionic net charge, and wherein the complex is not encapsulated in a nanocarrier. Another embodiment provides a method of delivering a biomacromolecule into a cell, which comprises providing a biomacromolecule as described herein, a hydrophobic counterion as described herein, and mixing the two under conditions effective to form a complex capable of entering a cell. Another embodiment provides a method of administering a biomacromolecule into a cell, which comprises providing the intracellular delivery complex of the present disclosure, and administering the intracellular delivery complex to a subject, such that the complex enters a cell of the subject.
Resumen de: US20260232781A1
0000 Described herein is a composition for immunization of a mammal against an infection by a parasite. The composition includes an extracellular vesicle produced by a red blood cell infected with the parasite; and a pharmaceutically acceptable carrier for parenteral administration. Also described herein is a method for immunizing a subject against an infection by a parasite. The method includes administering to the subject an effective amount of an extracellular vesicle exuded by the parasite, which resides with the host red blood cell.
Resumen de: US20260232589A1
A nanopreparation loaded with trabectedin and paclitaxel is provided. The nanopreparation loaded with trabectedin and paclitaxel includes a non-targeted drug-loaded micelle loaded with paclitaxel and a first targeting group linked to a first micelle carrier, where the non-targeted drug-loaded micelle has a first shell-core structure, and the first micelle carrier is prepared from poly(ε-caprolactone)-poly(2-ethyl-2-oxazoline) (PCL-PEOz), where a hydrophobic block of PCL and paclitaxel jointly form a core of the first shell-core structure, and a hydrophilic block of PEOz forms a shell of the first shell-core structure; and the first targeting group is linked via an amide bond formed between —NH2 on a surface of the first targeting group and —COOH at a terminus of the PEOz on a surface of the shell.
Resumen de: US20260232788A1
0000 The present invention relates to a dengue virus messenger ribonucleic acid (mRNA) vaccine. In particular, the vaccine includes an mRNA encoding a mutant envelop (E) protein of dengue virus at position 8 and/or 101 formulated in lipid nanoparticles. The mRNA vaccine of the present invention is safe and effective, which causes enhanced production of neutralizing antibodies against multiple serotypes of dengue virus and reduced antibody dependent enhancement (ADE) response.
Resumen de: US20260233124A1
0000 The present invention relates to methods for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid, comprising the steps of subjecting a solution containing said LNPs to a chromatographic medium with convective flow properties in the presence of at least one kosmotropic agent; and eluting LNPs from said chromatographic medium. The present invention further relates to respective uses of a chromatographic medium with convective flow properties for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid.
Resumen de: WO2026166561A1
Disclosed in the present application are an ionizable cationic lipid and the use thereof. In the ionizable cationic lipid of the present application, adsorption with a biological drug such as a nucleic acid is formed by means of the structural design of the head group, thereby improving the encapsulation efficiency, a branched structure is formed at the tail group by using a saturated or unsaturated fatty chain, and the head group and the tail group are linked by using an ester bond, which facilitates in-vivo degradation to reduce toxicity. The design of the unsaturated fatty chain increases the membrane fluidity during endosomal release, and effectively improves the release efficiency of a biological drug. Moreover, the ionizable cationic lipid of the present application has a good temperature stability, which not only improves the product quality, but also expands the product accessibility. In summary, the ionizable cationic lipid of the present application has the advantages of a high encapsulation efficiency, a low toxicity, a high endosomal release efficiency, a good temperature stability, etc., and can improve the quality and therapeutic effect of a lipid nanoparticle drug, thus providing a new solution and choice for biological drug delivery.
Resumen de: AU2025265466A1
Disclosed herein is a flowable polymer solution for intravascular (arterial and venous) administration comprising the polymer and at least one solvent, the polymer comprising a first monomer for binding water; a second monomer for imparting mechanical properties; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting thermoresponsive phase-transition behaviour. In an embodiment, the solution further comprises at least one radiographic intravenous contrast agent is selected from contrast media for digital subtraction angiography (DSA), computer tomography (CT) and fluoroscopy such as iodinated contrast media, tantalum, and bismuth-based materials (e.g., bismuth chelate), heavy metal chelates contrast media for MRI including gadolinium agents (e.g., gadobutrol) or MRI nanoparticles.
Nº publicación: US20260232847A1 13/08/2026
Solicitante:
CORNELL UNIV [US]
Cornell University
Resumen de: US20260232847A1
0000 Therapeutic methods, imaging methods, and inorganic nanotherapeutic imaging agents and inorganic nanoimaging agents. Inorganic nanotherapeutic imaging agents and inorganic nanoimaging agents are used in therapeutic methods and imaging methods. The inorganic nanotherapeutic imaging agents and inorganic nanoimaging agents are, for example, silica or aluminosilicate nanoparticles functionalized with fluorescent group(s), targeting groups, and therapeutic groups. Therapeutic methods can be used to treat and imaging methods can be used to investigate or diagnose inflammatory joint diseases, such as, for example, rheumatoid arthritis, osteoarthritis, or both, in a subject.
BOPI
Sede Electrónica
